Gartisertib

Overview

Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a K i of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 ( Chk1 ) phosphorylation with an IC 50 of 8 nM. Antitumor activity.

Application

Products | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lipid Metabolism | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > ATM/ATR

Product Information

• Catalog No.: HY-136270
• CAS No.: 1613191-99-3
• Molecular Formula: C25H29F2N9O3
• Molecular Weight: 541.55
• Purity: 99.77%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (3.84 mM); Clear solution
• Availability: In-stock

Source

Original product source